Gradient.png

CYT107 IL-7 a key growth factor for T-Cells

IL-7 improves survival in several animal models of viral, bacterial, and fungal infection.

IL-7 is the key non redundant factor for T cell production, proliferation, maturation and differentiation

As such IL-7 is the ideal therapeutic tool for all pathologies associated with lymphocytopenia and/or T cell exhaustion. Severe lymphocytopenia and T cells dysfunctions are associated with poor outcome (short survival) in oncology, hematology, sepsis and various infections.

IL-7 has multiple beneficial effects to improve host immunity in infectious diseases and cancer including T cell anti-apoptosis, strong increase of CD4 and CD8 T cells counts, increase of IFN-γ production and increase lymphocyte trafficking to tumors and/or sites of infection.

The double effect of IL-7 on CD4 and CD8 delivers warrants the production of very efficient immune responses against pathogens and malignant cells

CYT107 is the human recombinant IL-7 patented and developed by RevImmune (glycosylated protein produced from recombinant CHO cell)

IL-7 is a key factor to trigger and support immunotherapies in Oncology and Infectious diseases

IL-7 Profile

ONCOLOGY:

  • There is a strong rationale for Combo studies with Radiotherapy, Vaccines and Checkpoint inhibitors

  • IL-7 is currently tested in combination with Atezolizumab (anti-PDL-1) for treating urothelial cancer

  • IL-7 represents an exciting new approach to treat severe pathologies associated with lymphocytopenia and unlock the potential of various other immune therapies.

  • Quality and Stability of CYT107 Immune reconstitution is already demonstrated on more than 440 patients (HIV, HCV, Oncology, post-HSCT and Sepsis)

  • IL-7 has been well tolerated in 15 phase I/IIa clinical studies involving over 440 patients, systematically showing a broad immune reconstitution of T cells.

  • Many anti-viral, bacterial and malignant cells immune responses have already been documented in clinic

INFECTIOUS DISEASES:

 

IL-7 is currently being tested in phase 2 studies in:​

  • Sepsis

  • Viral (COVID-19)

  • Bacterial infections (non-tuberculosis mycobacterial infection)

© 2020 RevImmune. All Rights Reserved. Contact Us.

United States and Europe.